

2019 Future of Guillain-Barre Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2E612E9E6F7EN.html>

Date: February 2019

Pages: 40

Price: US\$ 2,199.00 (Single User License)

ID: 2E612E9E6F7EN

Abstracts

The global demand for Guillain-Barre Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Guillain-Barre Syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Guillain-Barre Syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.

Guillain-Barre Syndrome Report Description-

The 2019 pipeline study on Guillain-Barre Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Guillain-Barre Syndrome pipeline compounds.

The Guillain-Barre Syndrome pipeline guide presents information on all active drugs currently being developed for Guillain-Barre Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Guillain-Barre Syndrome pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Guillain-Barre Syndrome drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Guillain-Barre Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Guillain-Barre Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Guillain-Barre Syndrome pipeline report includes-

An overview of Guillain-Barre Syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Guillain-Barre Syndrome pipeline

Company wise list of Guillain-Barre Syndrome pipeline

Mechanism of Action wise Guillain-Barre Syndrome pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Guillain-Barre Syndrome pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Guillain-Barre Syndrome pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Guillain-Barre Syndrome pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL GUILLAIN-BARRE SYNDROME PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Guillain-Barre Syndrome Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Guillain-Barre Syndrome pipeline, H1- 2019
- 3.5 Mechanism of Action wise Guillain-Barre Syndrome Pipeline Candidates

4 AKARI THERAPEUTICS PLC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

- 4.1 Akari Therapeutics Plc Business Profile
- 4.2 Akari Therapeutics Plc Guillain-Barre Syndrome Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ALEXION PHARMACEUTICALS GULLAIN-BARRE SYNDROME PIPELINE DETAILS

- 5.1 Alexion Pharmaceuticals Business Profile
- 5.2 Alexion Pharmaceuticals Guillain-Barre Syndrome Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ANNEXON INC GULLAIN-BARRE SYNDROME PIPELINE DETAILS

- 6.1 Annexon Inc Business Profile
- 6.2 Annexon Inc Guillain-Barre Syndrome Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 CELLENKOS GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

- 7.1 Cellenkos Business Profile
- 7.2 Cellenkos Guillain-Barre Syndrome Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 COMPLEMENT PHARMA BV GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

- 8.1 Complement Pharma BV Business Profile
- 8.2 Complement Pharma BV Guillain-Barre Syndrome Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 CURAVAC INC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

- 9.1 CuraVac Inc Business Profile
- 9.2 CuraVac Inc Guillain-Barre Syndrome Drug Details

9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 HANSA MEDICAL AB GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

10.1 Hansa Medical AB Business Profile

10.2 Hansa Medical AB Guillain-Barre Syndrome Drug Details

10.3 Drug Snapshot

- 10.3.1 Originator
- 10.3.2 Collaborator/Co-Developer
- 10.3.3 Route of Administration
- 10.3.4 Orphan Drug/Fast Track/Special Designation
- 10.3.5 Geography
- 10.3.6 Type of Molecular Entity
- 10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 PRONOXIS GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

11.1 ProNoxis Business Profile

11.2 ProNoxis Guillain-Barre Syndrome Drug Details

11.3 Drug Snapshot

- 11.3.1 Originator
- 11.3.2 Collaborator/Co-Developer
- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation

- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 VITALITY BIOPHARMA INC GUILLAIN-BARRE SYNDROME PIPELINE DETAILS

- 12.1 Vitality Biopharma Inc Business Profile
- 12.2 Vitality Biopharma Inc Guillain-Barre Syndrome Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. LATEST GUILLAIN-BARRE SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019

14. APPENDIX

- 14.1 About Us
- 14.2 Sources and Methodology
- 14.3 Contact Information

I would like to order

Product name: 2019 Future of Guillain-Barre Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2E612E9E6F7EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2E612E9E6F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

